SeaStar Medical Holding Corporation (ICU) Q1 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights a fourfold revenue increase and a significant reduction in net loss, suggesting improved financial performance. The company is expanding its market presence with QUELIMMUNE and has a substantial market opportunity in adult AKI. Despite some regulatory and competitive risks, the management's optimistic outlook on faster approvals and pipeline growth is encouraging. The Q&A session revealed active engagement in clinical trials and expansion in pediatric sites, supporting a positive sentiment. Overall, the financial improvements and strategic positioning point to a potential 2% to 8% stock price increase.
Key Financial Performance
Revenue $293,000 (up from $68,000 in Q4 2024 and $0 in Q1 2024), a fourfold increase driven by greater adoption of QUELIMMUNE therapy from existing customers.
Operating Expenses $4.1 million (up from $3.9 million in Q1 2024), primarily due to increased spending for the commercial launch and growing enrollment in the NEUTRALIZE-AKI trial, partially offset by reduced G&A expenses.
Net Loss $3.7 million (down from $12.7 million in Q1 2024), reflecting improved revenue performance and cost management.
Cash Position Approximately $5.3 million at the end of Q1 2025, indicating a strengthened balance sheet with the addition of new capital.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
QUELIMMUNE Therapy Revenue: Achieved a fourfold increase in revenue compared to Q4 2024, totaling $293,000 in Q1 2025.
QUELIMMUNE Adoption: Increased adoption of QUELIMMUNE therapy among existing customers, with all existing customers purchasing during the quarter.
New Customer Acquisition: Added another prestigious nationally recognized Children's Hospital to QUELIMMUNE customer list.
SCD Therapy Pipeline: Received two new breakthrough device designations from the FDA for SCD therapy, expanding pipeline indications.
Pediatric AKI Market Opportunity: Estimated at $100 million annually in the U.S. for approximately 4,000 pediatric AKI patients.
Adult AKI Market Opportunity: Estimated at $4.5 billion annually in the U.S. for over 200,000 adult AKI patients.
NEUTRALIZE-AKI Trial Enrollment: Reached 50% enrollment milestone with 100 patients enrolled.
Cost Management: Lower sequential operating expenses while pushing forward NEUTRALIZE-AKI trial.
Commercial Strategy: Focus on acquiring new customers for QUELIMMUNE and expanding into the adult AKI market.
Future Plans: Anticipate filing a PMA for adult AKI indication in 2026.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Issues: The company is navigating the FDA approval process for its QUELIMMUNE therapy and the NEUTRALIZE-AKI trial, which includes a post-approval surveillance registry that requires additional IRB approval, potentially delaying adoption.
Supply Chain Challenges: The company anticipates that sales will be lumpy in the initial phase of the QUELIMMUNE launch, indicating potential supply chain or distribution challenges as they scale up production and distribution.
Market Competition: The company faces competition in the adult AKI market, which is significantly larger than the pediatric market, with over 200,000 adults affected annually, highlighting the need for effective differentiation.
Clinical Trial Risks: The NEUTRALIZE-AKI trial's slow enrollment rate poses a risk to timely completion, and the independent Data Safety Monitoring Board (DSMB) could recommend stopping the trial for futility or adjusting the sample size if results are not as expected.
Financial Risks: The company reported a net loss of $3.7 million in Q1 2025, indicating ongoing financial challenges as they invest in commercialization and clinical trials.
Economic Factors: The overall economic environment could impact hospital budgets and willingness to adopt new therapies, affecting the company's growth and revenue projections.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
QUELIMMUNE Customer Base Growth: The primary goal for 2025 is to grow the customer base for QUELIMMUNE therapy, with a focus on increasing adoption in pediatric medical facilities.
NEUTRALIZE-AKI Trial Progress: The NEUTRALIZE-AKI trial for adult patients has reached 50% enrollment, with plans to file a PMA for this indication in 2026.
Market Opportunity for Adult AKI: The adult AKI market represents a potential $4.5 billion annual opportunity in the U.S., with over 200,000 patients affected.
Breakthrough Device Designations: The company has received breakthrough device designations for five indications, expanding the potential market for SCD therapy.
Commercial Strategy: The strategy includes targeting the top 50 pediatric sites in the U.S. for QUELIMMUNE adoption and leveraging experiences from pediatric customers for adult AKI.
Q1 2025 Revenue: Revenue for Q1 2025 was $293,000, a fourfold increase from Q4 2024.
Future Revenue Expectations: Sales are expected to be lumpy initially but should trend upwards as more hospitals adopt QUELIMMUNE.
Operating Expenses: Operating expenses for Q1 2025 were $4.1 million, with a focus on commercial launch and trial enrollment.
Net Loss: Net loss for Q1 2025 was $3.7 million, down from $12.7 million in Q1 2024.
Cash Position: The company ended Q1 2025 with approximately $5.3 million in cash.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Quarterly Revenue: Revenue for the first quarter of 2025 was $293,000 compared to approximately $68,000 in the fourth quarter of 2024.
Net Loss: Net loss for the first quarter of 2025 declined to $3.7 million compared to a loss of $12.7 million in Q1 of 2024.
Market Opportunity for Adult AKI: The total market opportunity in the U.S. is approximately $4.5 billion.
Market Opportunity for Pediatric AKI: Estimated to be about $100 million total annual U.S. market opportunity based on a pediatric AKI population of approximately 4,000 patients.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you tell me how many sites are currently activated for the adult clinical trial?
A:Yes. We currently have 15 activated and probably another five that we plan to activate over the next three months.
Q:What's the total number of pediatric hospitals that you have as customers currently?
A:We have six sites that are commercially active and multiple others that are moving through the IRB process.
Q:What sort of pipeline growth have you seen in the first quarter compared to the fourth quarter?
A:It's a combination of things. It is experience that existing sites have. We have a way that these sites are able to communicate with each other and share their experiences and they're noticing a difference when they use QUELIMMUNE therapy.
Q:Can you just talk about how important these two additional breakthrough designations are and how you're prioritizing the various regulatory processes?
A:Cardiac surgery is one of the largest costs for hospitals in the country...we believe that this is a massive target of opportunity where we can make a big difference in these outcomes.
Q:So, it sounds like once you get this first adult approval that the subsequent ones are going to be able to move a lot more quickly?
A:Absolutely.
Q:Review of Unclear Management Responses
A:Management did not provide specific data on the pipeline growth compared to the previous quarter, and the response regarding the prioritization of regulatory processes was somewhat vague, lacking specific details on how resources will be allocated.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AKI CRRT
AKI trial
Chief
DSMB
FDA
NEUTRALIZE AKI
Officer
SCD therapy
SeaStar Medical
adoption
adult AKI
adult patient
analysis
approval
condition
customer
device designation
disease
effort
enrollment
goal
hospital
hyperinflammation
increase
indication
launch
life
market opportunity
milestone
number
organ
recommendation
result
site
today
treatment
ICU Transcript
SeaStar Medical Holding Corporation (ICU) Q1 2026 Earnings Call Transcript
Unknown5-13
The earnings call summary shows positive financial metrics, including a significant revenue increase and improved margins, but lacks guidance or strategic updates, creating uncertainty. The net loss, though reduced, and negative cash flow remain concerns. The absence of guidance, a common practice, may deter investors. Overall, the mixed signals and lack of clear future direction suggest a neutral stock price movement.
SeaStar Medical Holding Corporation (ICU) Q1 2025 Earnings Call Transcript
Positive5-14
The earnings call highlights a fourfold revenue increase and a significant reduction in net loss, suggesting improved financial performance. The company is expanding its market presence with QUELIMMUNE and has a substantial market opportunity in adult AKI. Despite some regulatory and competitive risks, the management's optimistic outlook on faster approvals and pipeline growth is encouraging. The Q&A session revealed active engagement in clinical trials and expansion in pediatric sites, supporting a positive sentiment. Overall, the financial improvements and strategic positioning point to a potential 2% to 8% stock price increase.
ICU Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
